Pharmacologic enhancement of α7nAChRs or targeted VNS results in neuroprotective effects, including reductions in oxidative stress, restoration of long-term potentiation (LTP), and improved cholinergic transmission in AD models [101]. The gene discussed is CHRNA7; the disease is Alzheimer disease.